LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer
Recruiting · NCT02511288 · Observational (researchers observe without assigning treatment) · Lead sponsor: Centre Leon Berard
View the official record on ClinicalTrials.gov →What this trial is about
The goal of this project is to characterize the genetic profile of patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) using liquid biopsies
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) regardless of the mutation status
- Inclusion at the time of diagnostic
- Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
- Age ≥ 18 years
- Covered by a health insurance
- Signed consent
Exclusion criteria
- \- Patients treated before their liquid biopsy
- COHORT 2 Inclusion criteria
- Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor Receptor (EGFR), B-Raf proto oncogene (BRAF) or Human Epidermal Growth Factor Receptor-2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS porto-oncogene 1 (ROS1) translocation, Mesenchymal-epithelial transition factor (MET) amplification, RET rearrangement.
- Inclusion at the time of diagnosis
- Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
- Age ≥ 18 years
- Covered by a health insurance
- Signed consent
- COHORT 3 Inclusion criteria
- Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) whatever the mutational or PD-L1 status.
- Inclusion at the time of immunotherapy treatment initiation (1st or 2nd line)
- Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
- Age ≥ 18 years
- Covered by a health insurance
- Signed consent
- Exclusion criteria
- \- Initiation of immunotherpy before their liquid biopsy
Where it is running
8 locations listed.
- Centre Hospitalier Annecy Genevois - Annecy, France
- CH Fleyriat - Bourg-en-Bresse, France
- Hôpital Louis Pradel - Bron, France
- CHU Grenoble Alpes - Grenoble, France
- Centre Léon Bérard - Lyon, France
- CHRU de Saint-Etienne - Saint-Priest-en-Jarez, France
- Institut de Cancérologie Lucien Neuwirth - Saint-Priest-en-Jarez, France
- Hôpital Nord Ouest - Villefranche-sur-Saône, France